PHF6 and mixed phenotype acute leukemia: We assigned the 44 T/myeloid MPAL patients into four groups including PHF6 and JAK/STAT comutation, single JAK/STAT or PHF6 mutation, and non-PHF6/JAK/STAT mutation (others), and found that the survival time of the PHF6 and JAK/STAT comutation group was significantly shorter than the single JAK/STAT mutation group (P < 0.0001) or the non-PHF6/JAK/STAT mutation group (P < 0.0001, Figs. 1E and S1A).